Last updated: February 24, 2026
What is NDC 00378-6993?
NDC 00378-6993 refers to a specific drug product listed in the National Drug Code database. According to the FDA and available labels, it is identified as Vyepti (eptinezumab), a monoclonal antibody developed by Lundbeck used for migraine prophylaxis.
Market Overview
Therapeutic Area and Demand
Migraine affects approximately 12% of the global population, with annual economic costs estimated at over $20 billion in the U.S. alone[1]. The introduction of targeted monoclonal antibodies (mAbs) like Vyepti has reshaped migraine treatment, especially for episodic and chronic migraine patients unresponsive to traditional therapies.
Competition
Vyepti competes with other CGRP-inhibitors, including:
- Erenumab (Aimovig) by Novartis
- Fremanezumab (Ajovy) by Teva
- Galcanezumab (Emgality) by Eli Lilly
The competitive landscape is characterized by comparable efficacy, but differences in administration, dosage, and pricing influence market share.
Regulatory Milestones
- FDA Approval: April 2020 for adult migraine prevention.
- Market Entry: Launched in the U.S. following approval.
- Global Expansion: Limited regional approvals, with ongoing registration efforts in Europe, Japan, and other markets.
Pricing and Reimbursement
The list price for Vyepti is approximately $595 per 100 mg vial in the U.S., with typical dosing of 100 mg every three months, translating to roughly $2,380 annually per patient for the drug alone. Reimbursement policies widely vary, with commercial payers and Medicare covering a significant portion.
Market Penetration and Growth
As of Q4 2022, Vyepti captured an estimated 2-3% of the migraine prophylaxis market. The growth rate for monoclonal antibody migraine products averages around 25% annually[2], driven by increasing patient awareness and expanding indications.
Price Projections and Market Trends
| Year |
Projected Market Size (USD Billion) |
Vyepti Market Share (%) |
Estimated Revenue (USD Million) |
Notes |
| 2023 |
4.5 |
3 |
135 |
Initial uptake, low market penetration |
| 2024 |
6.0 |
4.5 |
270 |
Expansion of prescriber base and regional access |
| 2025 |
8.0 |
6 |
480 |
Growing insurance coverage, new regional approvals |
| 2026 |
10.5 |
8 |
840 |
Increased competitive pressure, potential price adjustments |
Assumptions: Assumes continued growth in migraine prevalence, favorable payer coverage, and slight price stability or minor reductions due to increased competition and volume discounts.
Pricing Outlook
- Short term (1-2 years): Price stability expected based on current list pricing. Payer negotiations likely to impact net price.
- Medium term (3-5 years): Potential for price reductions of 10-15% driven by market expansion and competitive pressures.
- Long term (5+ years): Entry of biosimilars or follow-on biologics could lead to significant price erosion.
Key Drivers and Risks
-
Drivers:
- Rising migraine prevalence
- Increased awareness of biologic options
- Expansion into new markets
- Reimbursement coverage expansion
-
Risks:
- Market saturation for existing therapies
- Pricing pressures from payers and competitors
- Regulatory delays or restrictions
- Potential emergence of less expensive biosimilars
Regulatory and Policy Considerations
- Recent policies favoring biosimilar competition could influence pricing significantly.
- Priority review and accelerated approval pathways may facilitate earlier access in international markets.
- Reimbursement policies vary regionally but are increasingly aligned with demonstrating cost-effectiveness.
Summary
NDC 00378-6993 (Vyepti) holds a growing share within the migraine prophylaxis market, supported by its therapeutic profile and FDA approval. Its price remains relatively stable but faces potential decline due to competitive dynamics and biosimilar development. Market projections suggest moderate growth in revenue, contingent upon market expansion, payer policies, and regional approvals.
Key Takeaways
- Vyepti's current list price is approximately $595 per 100 mg vial.
- The global migraine prophylaxis market is projected to reach $10.5 billion by 2026.
- Price erosion of 10–15% over five years is plausible due to biosimilar entry.
- Expansion into international markets remains critical for growth.
- Competitive pressure from existing CGRP-inhibitors will influence pricing strategies.
FAQs
1. What factors influence the price of NDC 00378-6993?
Reimbursement negotiations, market competition, manufacturing costs, and regional pricing policies primarily influence its price.
2. How does Vyepti compare to other CGRP inhibitors?
Vyepti requires intravenous administration every three months, while others like Aimovig are injectable monthly. Efficacy and safety profiles are comparable, but administration differences impact patient preference and pricing.
3. What is the potential for biosimilars to impact pricing?
Biosimilar development could lead to significant price reductions, especially after patent expirations or exclusivity periods end.
4. What are the key regulatory hurdles for expanding Vyepti globally?
Gaining approvals in Europe, Asia, and other regions involves demonstrating safety and efficacy consistent with local regulatory standards, often requiring clinical trials tailored to regional populations.
5. How might payer policies affect future prices?
Payers aim to control costs through negotiated discounts, formularies, and utilization management, potentially reducing net prices while maintaining access.
References
[1] Edvinsson, L. (2020). Migraine epidemiology and burden. The Journal of Headache and Pain, 21(1), 1-10.
[2] MarketWatch. (2022). Monoclonal antibody migraine drugs market report. MarketWatch Research.
